4//SEC Filing
Ouimette Mike 4
Accession 0001209191-23-022376
CIK 0001746473other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 7:07 PM ET
Size
10.2 KB
Accession
0001209191-23-022376
Insider Transaction Report
Form 4
Ouimette Mike
General Counsel & Corp. Sec'y
Transactions
- Sale
Common Stock
2023-04-03$26.74/sh−2,677$71,575→ 50,989 total - Sale
Common Stock
2023-04-03$27.45/sh−200$5,491→ 50,789 total - Sale
Common Stock
2023-03-30$26.52/sh−4,874$129,263→ 53,666 total
Footnotes (5)
- [F1]Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.24 to $27.17, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $27.64, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
Documents
Issuer
PLIANT THERAPEUTICS, INC.
CIK 0001746473
Entity typeother
Related Parties
1- filerCIK 0001822619
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 7:07 PM ET
- Size
- 10.2 KB